Skip to main content
. Author manuscript; available in PMC: 2016 May 1.
Published in final edited form as: J Neuropathol Exp Neurol. 2015 May;74(5):442–452. doi: 10.1097/NEN.0000000000000188

Figure 3.

Figure 3

Effect of CDKN2A loss on overall survival in subsets of molecularly defined astrocytomas and oligodendrogliomas. (A–C) CDKN2A loss by fluorescence in situ hybridization (FISH) was associated with worse overall survival in IDH/TP53 mutated tumors with ATRX loss (IDH/TP53/ATRX group) (A) and IDH/TP53 mutated tumors (IDH/TP53 group) (B) but not in IDH mutated tumors with ATRX loss (IDH/ATRX group) (C). (D) Patients with molecularly defined oligodendrogliomas in the CDKN2A deleted group appeared to have improved survival; however, the statistical significance of the association between CDKN2A loss and overall survival could not be accurately assessed because none of the subjects in the CDKN2A deleted group died during the follow-up period.

HHS Vulnerability Disclosure